People of color are persistently underrepresented in global atopic dermatitis (AD) clinical trials, according to a research letter published in the British Journal of Dermatology.

Atopic dermatitis is well studied and known to be prevalent in developed nations; however, limited discussion evaluates the racial and ethnic disparities in global AD clinical trials. Consequently, in this study, researchers assessed enrollment and subgroup analyses of people of racial and ethnic minorities in published phase 2/3 randomized, double-blinded, placebo-controlled trials (RCTs) for AD during the past decade (January 2009-July 2019).